UFPT:NSC-UFP Technologies Inc. (USD)

EQUITY | Medical Devices | NASDAQ Capital Market

Last Closing

USD 247.03

Change

-5.36 (-2.12)%

Market Cap

USD 0.18B

Volume

0.04M

Analyst Target

USD 50.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

UFP Technologies Inc is a designer and custom converter of foams, plastics, composites and natural fiber materials, providing solutions to customers mainly within the medical, automotive, aerospace & defense, & packaging markets.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-23 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

N/A

USD 46.05B
ALGN Align Technology Inc

N/A

USD 19.27B
PODD Insulet Corporation

N/A

USD 13.41B
SWAV Shockwave Medical Inc

N/A

USD 12.57B
BRKR Bruker Corporation

N/A

USD 9.79B
MASI Masimo Corporation

N/A

USD 6.66B
TMDX TransMedics Group Inc

N/A

USD 4.52B
PRCT Procept Biorobotics Corp

N/A

USD 3.54B
AXNX Axonics Modulation Technologie..

N/A

USD 3.43B
TNDM Tandem Diabetes Care Inc

N/A

USD 3.20B

ETFs Containing UFPT

XHE SPDR® S&P Health Care Eq.. 2.06 % 0.35 %

N/A

USD 0.26B
RZG Invesco S&P SmallCap 600.. 0.00 % 0.35 %

N/A

USD 0.10B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 43.59% 84% B 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.59% 84% B 90% A-
Trailing 12 Months  
Capital Gain 62.92% 89% A- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 62.92% 89% A- 91% A-
Trailing 5 Years  
Capital Gain 562.46% 100% F 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 562.46% 100% F 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 47.23% 86% B+ 90% A-
Dividend Return 47.23% 86% B+ 90% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 34.08% 85% B 54% F
Risk Adjusted Return 138.57% 100% F 100% F
Market Capitalization 0.18B 86% B+ 80% B-

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 23.10 41% 24%
Price/Book Ratio 6.12 30% 18%
Price / Cash Flow Ratio 48.33 7% 6%
Price/Free Cash Flow Ratio 25.97 10% 9%
Management Effectiveness  
Return on Equity 17.68% 93% 88%
Return on Invested Capital 17.15% 88% 86%
Return on Assets 9.68% 98% 94%
Debt to Equity Ratio 9.79% 73% 71%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector